1. Home
  2. RGTI vs ABVX Comparison

RGTI vs ABVX Comparison

Compare RGTI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rigetti Computing Inc.

RGTI

Rigetti Computing Inc.

HOLD

Current Price

$22.02

Market Cap

10.9B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$133.80

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGTI
ABVX
Founded
2013
2013
Country
United States
France
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
9.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGTI
ABVX
Price
$22.02
$133.80
Analyst Decision
Buy
Strong Buy
Analyst Count
8
12
Target Price
$29.38
$115.83
AVG Volume (30 Days)
36.5M
1.8M
Earning Date
11-10-2025
08-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,494,000.00
$6,231,374.00
Revenue This Year
N/A
$6.80
Revenue Next Year
$167.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$4.77
52 Week High
$58.15
$148.83

Technical Indicators

Market Signals
Indicator
RGTI
ABVX
Relative Strength Index (RSI) 38.74 57.38
Support Level $21.53 $139.42
Resistance Level $22.96 $147.00
Average True Range (ATR) 1.77 7.25
MACD -0.03 0.98
Stochastic Oscillator 7.74 63.38

Price Performance

Historical Comparison
RGTI
ABVX

About RGTI Rigetti Computing Inc.

Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: